Top Suppliers:I want be here

  • DC Chemicals Limited
  • China
  • Product Name: AUDA
  • Price: $Inquiry/25mg $Inquiry/100mg $Inquiry/500mg
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao

479413-70-2

479413-70-2 structure
479413-70-2 structure
  • Name: AUDA
  • Chemical Name: 12-(1-adamantylcarbamoylamino)dodecanoic acid
  • CAS Number: 479413-70-2
  • Molecular Formula: C23H40N2O3
  • Molecular Weight: 392.575
  • Catalog: Research Areas Inflammation/Immunology
  • Create Date: 2017-06-22 13:07:03
  • Modify Date: 2024-01-04 13:14:14
  • AUDA (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor with IC50s of 18 and 69 nM for the mouse and human sEH, respectively[1]. AUDA has anti-inflammatory activity[2].

Name 12-(1-adamantylcarbamoylamino)dodecanoic acid
Synonyms 12-[[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]-dodecanoic acid
HMS2204E15
12-[(Adamantan-1-ylcarbamoyl)amino]dodecanoic acid
12-{[(3s,5s,7s)-Adamantan-1-ylcarbamoyl]amino}dodecanoic acid
Dodecanoic acid, 12-[[(tricyclo[3.3.1.1]dec-1-ylamino)carbonyl]amino]-
12-(3-adamantan-1-ylureido)dodecanoic acid
Urea-based compound,18
12-[(tricyclo[3.3.1.1]dec-1-ylcarbamoyl)amino]dodecanoic acid
AUDA
Description AUDA (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor with IC50s of 18 and 69 nM for the mouse and human sEH, respectively[1]. AUDA has anti-inflammatory activity[2].
Related Catalog
Target

IC50: 18 nM (mouse sEH) and 69 nM (human sEH)[1]

In Vitro AUDA (0.3-10 μg/mL; 48 hours) dose-dependently suppresses the proliferation of rat VSMCs exposed to PDGF[2]. AUDA (0.3-10 μg/mL; 30 min) dose-dependently upregulats COX-2 expression[2]. AUDA (10, 50 and 100 μM) augments the migratory ability of HCAECs in a dose-dependent manner[3]. AUDA significantly increases the adhesion ability of HCAECs[3]. Cell Proliferation Assay[2] Cell Line: Vascular smooth muscle cell (VSMC) Concentration: 0.3, 1, 3, 10 μg/mL Incubation Time: 48 hours Result: Dose-dependently suppressed the proliferation of rat VSMCs exposed to PDGF. Western Blot Analysis[2] Cell Line: VSMC Concentration: 1, 3, 10, 30 μg/mL Incubation Time: 30 min Result: Dose-dependently upregulated COX-2 expression.
In Vivo AUDA (i.p.; 10 mg/kg; 14 days) reduces TNF-α, MMP-9 and IL-1β expression levels[3]. Animal Model: Male (wild-type) C57BL/6 mice (age, 4-6 weeks; weight, 18-20 g)[3] Dosage: 10 mg/kg Administration: i.p.; 14 days Result: Reduced TNF-α, MMP-9 and IL-1β expression levels.
References

[1]. Morisseau C, et al. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases.Biochem Pharmacol. 2002 May 1;63(9):1599-608.

[2]. Kim HS, et al. Differential Effects of sEH Inhibitors on the Proliferation and Migration of Vascular Smooth Muscle Cells.Int J Mol Sci. 2017 Dec 11;18(12).

[3]. Dai N, et al. Vascular repair and anti-inflammatory effects of soluble epoxide hydrolase inhibitor.Exp Ther Med. 2019 May;17(5):3580-3588.

Density 1.1±0.1 g/cm3
Boiling Point 592.7±19.0 °C at 760 mmHg
Molecular Formula C23H40N2O3
Molecular Weight 392.575
Flash Point 312.3±21.5 °C
Exact Mass 392.303894
PSA 78.43000
LogP 5.61
Vapour Pressure 0.0±3.6 mmHg at 25°C
Index of Refraction 1.534
Storage condition -20℃
RIDADR NONH for all modes of transport

~98%

479413-70-2 structure

479413-70-2

Literature: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Patent: WO2006/45119 A2, 2006 ; Location in patent: Page/Page column 44; 52 ; WO 2006/045119 A2
Precursor  2

DownStream  0